File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Association between Acute-Phase Reactants and Advanced Glycation End Products in Type 2 Diabetes

TitleAssociation between Acute-Phase Reactants and Advanced Glycation End Products in Type 2 Diabetes
Authors
Issue Date2004
PublisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/
Citation
Diabetes Care, 2004, v. 27 n. 1, p. 223-228 How to Cite?
AbstractOBJECTIVE - Type 2 diabetes is associated with chronic low-grade inflammation, but the underlying mechanism(s) is not well understood. Because in vitro studies have shown that advanced glycation end products (AGEs) can trigger inflammatory responses, the present study has investigated whether serum concentration of AGEs is an important determinant of circulating levels of inflammatory markers, like C-reactive protein (CRP), in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - Diabetic patients (n = 210) and healthy control subjects (n = 110) of similar BMI were recruited. Serum AGEs were assayed by competitive enzyme-linked immunosorbent assay using a polyclonal rabbit anti-sera raised against AGE-RNase. Plasma high-sensitivity CRP was measured by an immunoturbidimetric assay and interleukin (IL)-6 by enzyme-linked immunosorbent assay. RESULTS - Serum AGEs were increased in diabetic patients compared with control subjects (4.24 ± 0.88 vs. 3.15 ± 0.81 unit/ml, respectively, P < 0.01). Both plasma CRP (1.55 [0.81-2.95] vs. 0.88 mg/dl [0.51-1.89], respectively, P < 0.01; median [interquartile range]) and IL-6 (0.80 [0.68-0.97] vs. 0.69 pg/ml [0.48-0.84], respectively, P < 0.01) were also higher in diabetic patients than in control subjects. In the diabetic patients, log(CRP) correlated with AGEs (r = 0.22, P = 0.002) and with log(IL-6) (r = 0.29, P < 0.001). Forward stepwise linear regression analysis showed that BMI, log(IL-6), and AGEs were significant independent determinants of log(CRP) in the diabetic patients, accounting for 17, 12, and 10% of the variation in log(CRP), respectively. CONCLUSIONS - Serum concentration of AGEs is increased in patients with diabetes and is an independent determinant of plasma CRP levels. Subclinical inflammation in these patients may therefore be partly due to activation of the inflammatory response by AGEs.
Persistent Identifierhttp://hdl.handle.net/10722/162761
ISSN
2015 Impact Factor: 8.934
2015 SCImago Journal Rankings: 5.827
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTan, KCBen_US
dc.contributor.authorChow, WSen_US
dc.contributor.authorTam, Sen_US
dc.contributor.authorBucala, Ren_US
dc.contributor.authorBetteridge, Jen_US
dc.date.accessioned2012-09-05T05:23:09Z-
dc.date.available2012-09-05T05:23:09Z-
dc.date.issued2004en_US
dc.identifier.citationDiabetes Care, 2004, v. 27 n. 1, p. 223-228en_US
dc.identifier.issn0149-5992en_US
dc.identifier.urihttp://hdl.handle.net/10722/162761-
dc.description.abstractOBJECTIVE - Type 2 diabetes is associated with chronic low-grade inflammation, but the underlying mechanism(s) is not well understood. Because in vitro studies have shown that advanced glycation end products (AGEs) can trigger inflammatory responses, the present study has investigated whether serum concentration of AGEs is an important determinant of circulating levels of inflammatory markers, like C-reactive protein (CRP), in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - Diabetic patients (n = 210) and healthy control subjects (n = 110) of similar BMI were recruited. Serum AGEs were assayed by competitive enzyme-linked immunosorbent assay using a polyclonal rabbit anti-sera raised against AGE-RNase. Plasma high-sensitivity CRP was measured by an immunoturbidimetric assay and interleukin (IL)-6 by enzyme-linked immunosorbent assay. RESULTS - Serum AGEs were increased in diabetic patients compared with control subjects (4.24 ± 0.88 vs. 3.15 ± 0.81 unit/ml, respectively, P < 0.01). Both plasma CRP (1.55 [0.81-2.95] vs. 0.88 mg/dl [0.51-1.89], respectively, P < 0.01; median [interquartile range]) and IL-6 (0.80 [0.68-0.97] vs. 0.69 pg/ml [0.48-0.84], respectively, P < 0.01) were also higher in diabetic patients than in control subjects. In the diabetic patients, log(CRP) correlated with AGEs (r = 0.22, P = 0.002) and with log(IL-6) (r = 0.29, P < 0.001). Forward stepwise linear regression analysis showed that BMI, log(IL-6), and AGEs were significant independent determinants of log(CRP) in the diabetic patients, accounting for 17, 12, and 10% of the variation in log(CRP), respectively. CONCLUSIONS - Serum concentration of AGEs is increased in patients with diabetes and is an independent determinant of plasma CRP levels. Subclinical inflammation in these patients may therefore be partly due to activation of the inflammatory response by AGEs.en_US
dc.languageengen_US
dc.publisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/en_US
dc.relation.ispartofDiabetes Careen_US
dc.subject.meshAcute-Phase Proteins - Metabolismen_US
dc.subject.meshBlood Pressureen_US
dc.subject.meshBody Constitutionen_US
dc.subject.meshBody Mass Indexen_US
dc.subject.meshCholesterol - Blooden_US
dc.subject.meshDiabetes Mellitus, Type 2 - Blood - Physiopathologyen_US
dc.subject.meshEnzyme-Linked Immunosorbent Assay - Methodsen_US
dc.subject.meshFemaleen_US
dc.subject.meshGlycosylation End Products, Advanced - Blooden_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshReference Valuesen_US
dc.subject.meshRegression Analysisen_US
dc.subject.meshTriglycerides - Blooden_US
dc.titleAssociation between Acute-Phase Reactants and Advanced Glycation End Products in Type 2 Diabetesen_US
dc.typeArticleen_US
dc.identifier.emailTan, KCB:kcbtan@hku.hken_US
dc.identifier.authorityTan, KCB=rp00402en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.2337/diacare.27.1.223en_US
dc.identifier.pmid14693993-
dc.identifier.scopuseid_2-s2.0-1042280188en_US
dc.identifier.hkuros88343-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-1042280188&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume27en_US
dc.identifier.issue1en_US
dc.identifier.spage223en_US
dc.identifier.epage228en_US
dc.identifier.isiWOS:000187632200038-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridTan, KCB=8082703100en_US
dc.identifier.scopusauthoridChow, WS=7402281153en_US
dc.identifier.scopusauthoridTam, S=7202037323en_US
dc.identifier.scopusauthoridBucala, R=7102379822en_US
dc.identifier.scopusauthoridBetteridge, J=7004113903en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats